Today's Highlights
Premium
BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions
BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. ( BBIO ) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 s...
P
Prohost Biotech
1 min read
13
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion